MCI-154, a Ca2+ sensitizer, increases survival in cardiomyopathic hamsters.
To assess the long-term efficacy of a Ca2+ sensitizer MCI-154, 6-[4-(4'-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride trihydrate, on chronic heart failure, we studied the effects of the agent on the life span of cardiomyopathic hamsters of the BIO-14.6 strain. At approximately 150 days of age, 210 male hamsters were randomly divided into three groups: MCI-154 0.1 mg kg(-1), day(-1)(MCI-154-low), MCI-154 1 mg kg(-1) day(-1) (MCI-154-high), and control group. The median survival time in control, MCI-154-low and MCI-154-high groups was 227, 243 and 260 days after the start of treatment, respectively. Final survival rate at 284 days in control, MCI-154-low and MCI-154-high groups was 0, 17.1 and 38.6%, respectively. The cumulative survival times in the two MCI-154 treated groups were significantly prolonged in comparison with that in the control group (P < 0.0001). Thus, the present study clearly showed that MCI-154 prolonged the life span of cardiomyopathic hamsters, suggesting that long-term therapy with MCI-154 would be promising in the treatment of congestive heart failure.
Kawasumi
H
H
Pharmaceuticals Laboratory I, Yokohama Research Center, Mitsubishi Chemical Corporation, Japan.
Abe
Y
Y
Ishibashi
A
A
Kitada
Y
Y
D000818:Animals; D002118:Calcium / Q000378:metabolism*; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006224:Cricetinae; D004195:Disease Models, Animal; D008297:Male; D008647:Mesocricetus; D011724:Pyridazines / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D011724:Pyridazines; C052228:MCI 154; D002118:Calcium